METHOCARBAMOL AND ASPIRIN
Clinical safety rating
safeCNS depressants may enhance sedative effects Can cause discoloration of urine.
Methocarbamol is a centrally acting muscle relaxant whose exact mechanism is unknown but may involve general CNS depression. Aspirin irreversibly inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin and thromboxane synthesis, resulting in analgesic, antipyretic, anti-inflammatory, and antiplatelet effects.
| Metabolism | Methocarbamol is metabolized via dealkylation and hydroxylation, primarily by CYP450 enzymes (CYP2C9, CYP1A2, CYP2D6) and undergoes Phase II conjugation. Aspirin is rapidly hydrolyzed to salicylic acid by esterases in plasma and liver; salicylic acid is primarily conjugated with glycine (salicyluric acid) and glucuronic acid, with minor oxidation. |
| Excretion | Methocarbamol: Renal excretion of glucuronide and sulfate conjugates (95%) with <5% unchanged. Aspirin: Renal excretion of salicylic acid and metabolites (primarily salicyluric acid and glucuronides) with ~50% as salicylate at alkaline pH; biliary elimination <5%. |
| Half-life | Methocarbamol: 1–2 hours (terminal). Aspirin: 15–20 minutes for parent drug; salicylic acid: 2–3 hours (low doses) to 15–30 hours (high doses, due to saturable metabolism). Combined product: consider aspirin's longer terminal half-life at therapeutic doses. |
| Protein binding | Methocarbamol: 46–50% (mainly albumin). Aspirin: 80–90% (albumin; salicylate binding is concentration-dependent, 50–90%). |
| Volume of Distribution | Methocarbamol: 0.7–0.8 L/kg (distributes into total body water). Aspirin: 0.15–0.2 L/kg for salicylate at therapeutic doses, increasing to >0.3 L/kg at toxic levels (tissue accumulation). |
| Bioavailability | Methocarbamol: Oral bioavailability ~100% (well absorbed). Aspirin: Oral bioavailability 40–50% (first-pass hydrolysis to salicylate; enteric-coated forms may have delayed absorption). |
| Onset of Action | Oral methocarbamol: ~30 minutes. Oral aspirin: analgesic/antipyretic 30–60 minutes; antiplatelet effect within 1 hour. Combined: onset likely dominated by aspirin's effects. |
| Duration of Action | Methocarbamol: 4–6 hours (muscle relaxation). Aspirin: analgesic/antipyretic 3–6 hours; antiplatelet effect ~7–10 days (irreversible COX-1 inhibition). Clinical muscle relaxation lasts 4–6 hours. |
| Molecular Weight | Aspirin: 180.16 Da; Methocarbamol: 241.24 Da |
1 to 2 tablets (methocarbamol 400 mg / aspirin 325 mg per tablet) orally every 4-6 hours as needed, not to exceed 6 tablets per day.
| Dosage form | TABLET |
| Renal impairment | CrCl <50 mL/min: avoid aspirin component (risk of accumulation and toxicity). Methocarbamol may require cautious use with monitoring. CrCl <30 mL/min: contraindicated (aspirin); methocarbamol not recommended. |
| Liver impairment | Child-Pugh Class A: no change. Child-Pugh Class B: reduce dose by 50% or prolong interval. Child-Pugh Class C: contraindicated (risk of bleeding and hepatotoxicity). |
| Pediatric use | Not recommended in children <12 years due to aspirin's risk of Reye's syndrome. For ≥12 years: same as adult (1-2 tablets every 4-6 hours, max 6 tablets/day). |
| Geriatric use | Elderly patients: start with lowest dose (1 tablet every 6 hours) due to increased sensitivity and higher risk of bleeding with aspirin; monitor renal function and consider avoiding chronic use. |
| 1st trimester | Aspirin: Avoid high doses (>=325 mg/day) due to risk of congenital malformations; low doses may be used if indicated. Methocarbamol: Limited human data, animal studies show no clear risk; use only if clearly needed. |
| 2nd trimester | Aspirin: Avoid high doses due to risk of premature closure of ductus arteriosus; use low doses only if indicated. Methocarbamol: Limited data, generally avoided. |
| 3rd trimester | Aspirin: Contraindicated at full doses due to risk of premature closure of ductus arteriosus, oligohydramnios, and perinatal hemorrhage. Low doses may still pose risks. Methocarbamol: Avoid due to lack of safety data. |
Clinical note
CNS depressants may enhance sedative effects Can cause discoloration of urine.
| FDA category | Animal |
| Placental transfer | Both aspirin and methocarbamol cross the placenta. Aspirin readily crosses; methocarbamol transfer is documented in animals. |
| Breastfeeding | Aspirin is excreted into breast milk in low amounts; high doses might increase risk of Reye's syndrome in infants. Methocarbamol is excreted in breast milk; avoid use in nursing mothers due to potential effects on infant. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | First trimester: Aspirin is associated with increased risk of miscarriage and congenital malformations (e.g., gastroschisis) at high doses; methocarbamol has limited data, but no major teratogenicity reported. Second trimester: Aspirin may cause premature closure of ductus arteriosus at high doses; methocarbamol safety uncertain. Third trimester: Aspirin increases risk of intracranial hemorrhage in neonate and premature closure of ductus arteriosus; avoid use after 30 weeks. Methocarbamol: no known specific fetal risks, but avoid in late pregnancy due to potential maternal muscle relaxation effects. |
| Fetal Monitoring | Monitor maternal bleeding time, platelet function, and signs of gastrointestinal bleeding. Fetal ultrasound to assess ductus arteriosus and amniotic fluid index if used in third trimester. Monitor for preterm labor or uterine atony. |
| Fertility Effects | Aspirin at high doses may impair ovulation (reversible). Methocarbamol has no known effects on fertility. Combined effect not specifically studied. |
■ FDA Black Box Warning
Reye's syndrome: Aspirin should not be used in children or teenagers with viral infections due to risk of Reye's syndrome.
| Common Effects | Drowsiness |
| Serious Effects |
Hypersensitivity to salicylates or methocarbamolBleeding disorders (e.g., hemophilia, thrombocytopenia)Active peptic ulcer diseaseSevere hepatic impairmentSevere renal impairment (CrCl <30 mL/min)Third trimester of pregnancy (aspirin at full doses)Children with viral infections (Reye's syndrome risk)G6PD deficiency (aspirin may cause hemolysis)
| Precautions | Salicylate toxicity (tinnitus, hyperventilation, metabolic acidosis); bleeding risk (aspirin antiplatelet effect); hepatic impairment; renal impairment; GI bleeding; pregnancy (avoid in third trimester); nursing mothers; hypersensitivity to NSAIDs; concomitant use of methotrexate or anticoagulants; Reye's syndrome risk in pediatric viral illness. |
| Food/Dietary | Avoid alcohol (increases CNS depression and GI bleeding risk). Take with food or milk to minimize gastric irritation. Avoid high-dose vitamin C or acidic foods that may increase aspirin absorption and toxicity. |
| Clinical Pearls | Methocarbamol is a centrally acting muscle relaxant; aspirin is an NSAID. Onset of methocarbamol is rapid (30 min) with peak at 2 hours. Aspirin component may increase bleeding risk, especially with alcohol or anticoagulants. Avoid in children with viral illness due to Reye's syndrome risk. Max aspirin dose 4g/day. |
| Patient Advice | Take with food to reduce GI upset. · Avoid alcohol and other CNS depressants. · May cause drowsiness or dizziness; avoid driving. · Do not use in children or teenagers with chickenpox or flu symptoms. · Stop and seek medical attention if signs of bleeding or allergic reaction occur. |
Loading safety data…